Company intelligence / Profile preview

Kaiskaidi

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Kaiskaidi is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for metabolic and renal diseases. The company's lead programs target chronic kidney disease (CKD) and hyperuricemia, utilizing highly selective mineralocorticoid receptor antagonists and xanthine oxidase inhibitors. Kaiskaidi aims to address significant unmet medical needs in the treatment of diabetic nephropathy and gout through optimized pharmacological profiles. Headquartered in Suzhou, China, the company leverages a team with extensive global pharmaceutical experience to advance its pipeline through clinical validation.

Therapeutic areas: RheumatologyMetabolic DisordersNephrology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Kaiskaidi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaiskaidi.

Explore the full profile